Industrie Biomediche Insubri SA (IBI) in a collaboration with The Pharmaceutical and Biomedical Technologies laboratory, within the Institute CIM for Sustainable Innovation of the University of Applied Sciences and Arts of Southern Switzerland (SUPSI) (www.supsi.ch/icimsi), and Corticalis AS (www.corticalis.com), a Norwegian R&D company focused on bone regenerative technologies and biomaterials, won the Eurostars Project – E!9624.
The goal of the project is the development of a new composite bone substitute for the regeneration of bone defects and losses in paediatric applications, including oncological ones, achieving the conditions for clinical studies.
A composite approach will be followed to obtain a multicomponent device where a commercially available composite xenograft-synthetic bone substitute (SmartBone®) will be integrated with new and highly effective osteoinductive synthetic peptides (NuPep™).
The new device (SmartBonePep®) will be the main result of the project. It will be achieved by means of an innovative integration of two existing components SmartBone® and NuPep™.
Following a successful clinical study the consortium will sell on the market its new medical device (SmartBonePep®).
This innovative medical device is directed to the paediatric bone regeneration market.
No satisfactory solutions for paediatric patients are today available, where main paediatric bone needs could be grouped in the following 3 categories:
For further information please visit the dedicated website Visit the website!
The Eurostars Programme (www.eurostars-eureka.eu) is the European funding and support programme specifically dedicated to stimulating international collaborative research and innovation projects of small and medium enterprises.